Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases

被引:255
作者
Pettipher, Roy
Hansel, Trevor T.
Armer, Richard
机构
[1] Oxagen Ltd, Abingdon OX14 4RY, Oxon, England
[2] Royal Brompton Hosp, Natl Heart & Lung Inst, Clin Studies Unit, London SW3 6HP, England
关键词
D O I
10.1038/nrd2266
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Immunological activation of mast cells is an important trigger in the cascade of inflammatory events leading to the manifestation of allergic diseases. Pharmacological studies using the recently discovered DP1 and CRTH2 antagonists combined with genetic analysis support the view that these receptors have a pivotal role in mediating aspects of allergic diseases that are resistant to current therapy. This Review focuses on the emerging roles that DP1 and CRTH2 ( also known as DP2) have in acute and chronic aspects of allergic diseases and proposes that, rather than having opposing actions, these receptors have complementary roles in the initiation and maintenance of the allergy state. We also discuss recent progress in the discovery and development of selective antagonists of these receptors.
引用
收藏
页码:313 / 325
页数:13
相关论文
共 134 条
[41]  
Fretz H, 2005, Patent No. [2005095397, WO 2005095397 A1]
[42]   A physicogenetic method to assign ligand-binding relationships between 7TM receptors [J].
Frimurer, TM ;
Ulven, T ;
Elling, CE ;
Gerlach, LO ;
Kostenis, E ;
Högberg, T .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (16) :3707-3712
[43]   Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice [J].
Fujitani, Y ;
Kanaoka, Y ;
Aritake, K ;
Uodome, N ;
Okazaki-Hatake, K ;
Urade, Y .
JOURNAL OF IMMUNOLOGY, 2002, 168 (01) :443-449
[44]   Δ12-Prostaglandin D2 is a potent and selective CRTH2 receptor agonist and causes activation of human eosinophils and Th2 lymphocytes [J].
Gazi, L ;
Gyles, S ;
Rose, J ;
Lees, S ;
Allan, C ;
Xue, LZ ;
Jassal, R ;
Speight, G ;
Gamble, V ;
Pettipher, R .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2005, 75 (1-4) :153-167
[45]  
Ghosh S., 2004, PGD2 receptor antagonists for the treatment of inflammatory diseases, Patent No. [WO 2004032848, 2004032848]
[46]  
Ghosh S., 2005, PGD2 receptor antagonists for the treatment of inflammatory diseases, Patent No. [WO 2005100321, 2005100321]
[47]   THE CLASSIFICATION OF PROSTAGLANDIN DP-RECEPTORS IN PLATELETS AND VASCULATURE USING BW-A868C, A NOVEL, SELECTIVE AND POTENT COMPETITIVE ANTAGONIST [J].
GILES, H ;
LEFF, P ;
BOLOFO, ML ;
KELLY, MG ;
ROBERTSON, AD .
BRITISH JOURNAL OF PHARMACOLOGY, 1989, 96 (02) :291-300
[48]   Inducible cyclooxygenase may have anti-inflammatory properties [J].
Gilroy, DW ;
Colville-Nash, PR ;
Willis, D ;
Chivers, J ;
Paul-Clark, MJ ;
Willoughby, DA .
NATURE MEDICINE, 1999, 5 (06) :698-701
[49]   Prostaglandin D2 affects the differentiation and functions of human dendritic cells:: impact on the T cell response [J].
Gosset, P ;
Pichavant, M ;
Faveeuw, C ;
Bureau, F ;
Tonnell, AB ;
Trottein, F .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (05) :1491-1500
[50]   Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities [J].
Grosser, T ;
Fries, S ;
FitzGerald, GA .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (01) :4-15